ELDN
NASDAQ · Biotechnology
Eledon Pharmaceuticals Inc
$3.94
+0.06 (+1.55%)
Open$3.87
Previous Close$3.88
Day High$4.00
Day Low$3.83
52W High$4.60
52W Low$1.35
Volume—
Avg Volume1.81M
Market Cap291.77M
P/E Ratio—
EPS$-0.83
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+206.9% upside
Current
$3.94
$3.94
Target
$12.09
$12.09
$9.42
$12.09 avg
$15.53
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 30.92M | 31.36M | 28.49M |
| Net Income | 5.14M | 5.83M | 4.48M |
| Profit Margin | 16.6% | 18.6% | 15.7% |
| EBITDA | 8.25M | 8.46M | 8.04M |
| Free Cash Flow | 7.08M | 5.83M | 4.28M |
| Rev Growth | +12.9% | -8.9% | -3.6% |
| Debt/Equity | 0.35 | 0.38 | 0.34 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |